Jemal A, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96. (Pubitemid 351521864)
Bookman MA, et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27(9):1419-1425.
Harfe BD (2005) MicroRNAs in vertebrate development. Curr Opin Genet Dev 15(4):410-415.
Vecchione A, Croce CM (2010) Apoptomirs: Small molecules have gained the license to kill. Endocr Relat Cancer 17(1):F37-F50.
Carleton M, Cleary MA, Linsley PS (2007) MicroRNAs and cell cycle regulation. Cell Cycle 6(17):2127-2132. (Pubitemid 47450412)
Poy MN, et al. (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432(7014):226-230. (Pubitemid 39545853)
Volinia S, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257-2261. (Pubitemid 43271657)
Petrocca F, et al. (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13(3):272-286. (Pubitemid 351318375)
Visone R, et al. (2007) Specific microRNAs are downregulated in human anaplastic carcinomas. Oncogene 26:7569-7595.
Lu J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834-838. (Pubitemid 40839735)
Yanaihara N, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3):189-198. (Pubitemid 43357945)
Mattie MD, et al. (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24.
Takamizawa J, et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11):3753-3756. (Pubitemid 38697282)
Olofsson B, et al. (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93(6):2576-2581. (Pubitemid 26104389)
Olsson AK, Dimberg AD, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7(5):359-371.
Suhonen KA, et al. (2007) Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer. Eur J Cancer 43(8):1300-1307. (Pubitemid 46720248)
Cortez MA, et al. (2011) MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8):467-477.
Dahiya N, Morin PJ (2010) MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 17(1):F77-F89.
Shih KK, et al. (2011) A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 121(3):444-450.
Jain RK (2005) Normalization of tumor vasculature: An emerging concept in anti-angiogenic therapy. Science 307(5706):58-62.
Escorcia FE, et al. (2010) Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 70(22):9277-9286.
Delli Carpini J, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13(1):43-58.
Sowter HM, et al. (1997) Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 77(6):607-614. (Pubitemid 28018781)
Sallinen H, et al. (2009) Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther 17(2):278-284.
Stone RL, Sood AK, Coleman RL (2010) Collateral damage: Toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 11(5):465-475.
Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM, Jr. (2011) At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29(10):1247-1251.
Perren TJ, et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484-2496.
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603.
Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J (2011) Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm 8(1):250-259.
Eisenhauer EA, et al. (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247.
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101-1108. (Pubitemid 351818697)
